CBL-514 — Investigational Injectable for Targeted Fat Reduction

First-in-Class Small-Molecule Drug Candidate | Adipocyte Apoptosis | Localized Adipose Tissue Research

Product Overview

CBL-514 is a first-in-class investigational injectable small-molecule drug candidate developed by Caliway Biopharmaceuticals for the targeted reduction of localized subcutaneous fat.

Unlike conventional weight-management strategies, such as dietary modification, physical exercise, or incretin-based medications including semaglutide and tirzepatide, CBL-514 is designed to act directly on adipose tissue by inducing adipocyte apoptosis — the programmed death of fat cells.

This targeted mechanism represents a distinct experimental approach to localized fat reduction, with potential applications in non-surgical body contouring and adipose tissue research.

CBL-514 is administered through localized subcutaneous injections under investigational clinical protocols. Its clinical effectiveness, tissue selectivity, durability of response, and long-term safety remain under evaluation.

Mechanism of Action

CBL-514 is being developed to induce programmed cell death in targeted adipocytes, potentially reducing localized fat tissue volume.

Its proposed mechanism involves three principal areas of investigation:

• Adipocyte Apoptosis: CBL-514 is designed to activate biological processes associated with programmed fat cell death. The precise contribution of individual molecular pathways continues to be evaluated through scientific research.

• Targeted Subcutaneous Fat Reduction: By inducing apoptosis in adipocytes within the treated region, CBL-514 aims to reduce localized subcutaneous fat volume. However, the elimination of targeted fat cells does not guarantee permanent cosmetic results, as remaining adipocytes may enlarge and adipose tissue can accumulate again.

• Tissue Selectivity and Local Tolerability: Available preclinical and clinical findings suggest potentially favorable local tolerability under studied conditions. Further investigation is required to fully characterize tissue selectivity, systemic exposure, rare adverse events, and long-term safety.

Research Focus: CBL-514 is being investigated as a localized adipose tissue intervention rather than a conventional appetite-suppressing or systemic weight-loss medication.

Clinical Research & Trial Findings

CBL-514 has been evaluated in clinical trials investigating non-surgical subcutaneous fat reduction.

Research findings reported in connection with the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting included the following results.

Research Parameter	Reported Clinical Findings
Subcutaneous Fat Reduction	In a Phase 2 study, 69.6% of CBL-514-treated participants achieved a reduction of at least 150 mL of subcutaneous fat in the treated area at the eight-week assessment.
Placebo Comparison	No participants in the placebo group achieved the same reduction threshold at the eight-week assessment.
Visceral Fat — Initial Follow-Up	In an MRI-assessed subgroup of Phase 2 trial participants, mean visceral adipose tissue volume decreased by 12.01% from baseline.
Visceral Fat — Subsequent Follow-Up	Mean visceral adipose tissue volume remained 10.45% below baseline at the later assessment.
Visceral Fat — Placebo Group	Mean visceral adipose tissue volume increased by 5.68% at the initial follow-up and by 11.76% at the subsequent assessment.

Clinical Interpretation

These reported findings suggest that CBL-514 may have measurable effects on adipose tissue volume in selected clinical trial populations.

However, the visceral fat results were derived from a subgroup of participants with available MRI measurements. They should therefore be considered preliminary clinical findings rather than definitive evidence of efficacy.

Larger controlled studies are necessary to establish the reproducibility, clinical relevance, durability, and safety of these observations.

Potential Clinical Research Applications

CBL-514 is being investigated across several areas of adipose tissue biology and therapeutic development.

1. Localized Subcutaneous Fat Reduction

Investigation of CBL-514 as a non-surgical approach to reducing localized subcutaneous fat deposits, particularly in abdominal regions.

Although potentially relevant to aesthetic medicine, CBL-514 has not been established or approved as an alternative to liposuction.

2. Visceral Adipose Tissue Research

Exploration of whether CBL-514 may influence visceral adipose tissue volume.

Preliminary MRI findings have generated scientific interest, but additional controlled studies are required to confirm these observations and determine their clinical significance.

3. Combination Research with Incretin-Based Therapies

Preclinical investigations have explored the combination of CBL-514 with tirzepatide, a dual GIP/GLP-1 receptor agonist.

Animal research has suggested potential effects on weight reduction and weight regain following treatment discontinuation.

A Phase 2 clinical development program is investigating this combination. The proposed benefits have not yet been established in humans.

4. Cellulite and Other Adipose Tissue Conditions

Research programs have also explored CBL-514 for additional adipose tissue-related indications, including cellulite.

A separate formulation, CBL-514D, is under investigation for Dercum's disease, a rare disorder associated with painful fatty tissue deposits and lipomas.

These programs represent investigational applications and do not imply regulatory approval or established therapeutic effectiveness.

Clinical Development & Regulatory Status

As of October 2026, CBL-514 remained an investigational pharmaceutical candidate without regulatory approval for routine clinical use or commercial distribution as an approved medicine.

Its global Phase 3 development program includes the SUPREME-01 clinical trial, designed to evaluate the efficacy and safety of CBL-514 for non-surgical reduction of abdominal subcutaneous fat.

Regulatory authorization will depend on the results of clinical development, comprehensive safety assessments, and review by the relevant regulatory authorities.

Safety & Tolerability

Clinical studies reported to date have generally described CBL-514 as tolerable within the specific populations and treatment conditions evaluated.

The most frequently reported adverse events have included temporary, mild-to-moderate injection-site reactions, such as:

• Localized pain or discomfort

• Swelling at the injection site

• Redness and temporary skin reactions

These findings do not establish the absence of serious adverse events or confirm long-term safety.

Important Safety Considerations

• Investigational Status: CBL-514 has not been approved for routine therapeutic or aesthetic use.

• Incomplete Long-Term Safety Data: Potential delayed adverse effects and long-term tissue responses remain under investigation.

• Uncertain Durability: Permanent elimination of localized fat deposits has not been clinically established.

• Limited Generalizability: Clinical trial results may not apply to populations outside those studied.

• Administration-Related Risks: Injection procedures may involve additional risks that require evaluation and appropriate clinical oversight.

CBL-514 should not be represented as an approved weight-loss medication, a proven substitute for liposuction, or a treatment capable of guaranteeing permanent localized fat reduction.

Scientific Research & Development Perspective

CBL-514 represents an emerging investigational approach in adipose tissue pharmacology.

By focusing on adipocyte apoptosis rather than appetite regulation or caloric intake, the compound introduces a different strategy for exploring localized fat reduction.

Although early clinical findings are encouraging, its therapeutic potential remains dependent on successful clinical development, confirmation of meaningful clinical benefits, and comprehensive safety evaluation.

Research Use Only

FOR AUTHORIZED SCIENTIFIC AND CLINICAL RESEARCH PURPOSES ONLY.

CBL-514 is an investigational pharmaceutical compound intended for use exclusively within legitimate scientific research and appropriately authorized clinical investigation.

• Not approved for general human or veterinary use.

• Not intended for personal injection or self-administration.

• Not intended for unsupervised aesthetic or weight-loss procedures.

• Not authorized for routine clinical treatment or commercial therapeutic use.

• Not established as safe or effective for diagnosing, treating, curing, or preventing any disease.

The designation “Research Use Only” does not replace applicable pharmaceutical regulations, clinical trial authorization requirements, or legal restrictions governing investigational medicines.

PEPTITAN — PRECISION. SCIENCE. RESEARCH.

Scientific information provided for educational and research purposes. Clinical findings are preliminary and should be interpreted in the context of their original study designs, patient populations, and published evidence.